Sacubitril/valsartan compared to ramipril in high ‐risk post myocardial infarction patients stratified according use of mineralocorticoid receptor antagonists: Insight from PARADISE MI trial

ConclusionsUse of a MRA did not modify safety or clinical endpoints related to initiation of ARNI compared to ramipril in the post MI setting in patients with LVSD and/or congestion.This article is protected by copyright. All rights reserved.

Source: European Journal of Heart Failure - November 7, 2023 Category: Cardiology Authors: Morten Schou, Brian Claggett, Zi Michael Miao, Alberto Fernandez, Gerasimos Filippatos, Christopher Granger, Karola Jering, Aldo P. Maggioni, Finnian McCausland, Julio Nu ñez Villota, Jean‐Lucien Rouleau, Freny Vaghaiwalla Mody, Peter van d Tags: Research Article Source Type: research